“These data from VERITAC-2 support the potential of vepdegestrant to give patients whose tumors harbor ESR1 mutations additional time without disease progression, compared to fulvestrant.

Around 70% of all metastatic breast cancer cases are HR-positive and HER2-negative, and ESR1 mutations are found in up to 40% of these tumours. That suggests there should be plenty of eligible ...